Shanghai Pharmaceuticals (601607.SH) has announced that its subsidiary, Shanghai SPH First Biochemical Pharmaceutical Co., Ltd., recently received a Drug Registration Certificate from the National Medical Products Administration for Clevidipine Emulsion Injection, granting approval for the drug's production.
The drug is primarily indicated for the treatment of hypertension in patients who are not suitable for oral therapy or who are expected to respond poorly to oral medication.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments